![[ Visit Client Website ]](images/banner.gif)
Monday, 30 July 2012
Learning Objective 1: The learner will be able to know new evidences on fatigue and QOL of breast cancer patients receiving hormonal therapy in Japan.
Learning Objective 2: The learner will be able to know the relationship between fatigue and QOL in breast cancer receiving hormone therapy in Japan.
BACKGROUND: Patients with breast cancer are likely to develop symptoms such as fatigue due to hormone therapy and experience a decline in quality of life (QOL). OBJECTIVES: To assess the fatigue levels and QOL in breast cancer patients receiving hormone therapy in outpatient departments in comparison with those of healthy women. METHODS: The study included 303 breast cancer patients receiving hormone therapy and 200 healthy women. The survey was conducted by using questionnaires: (1) subject characteristics; (2) Japanese version of the European Organization for Research Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Core 30 version 3; (3) Japanese version of the EORTC QLQ-Breast 23; (4) fatigue subscales of Japanese version of the Profile of Mood States (POMS); and (5) Japanese version of the Brief Fatigue Inventory (BFI). RESULTS: The average BFI score of the breast cancer patients was 3.14, and there was a significant difference in the average scores between the patients and healthy women. The average POMS fatigue scale score in breast cancer patients in the present study was 10.37, and there was a significant difference between the scores of patients and healthy women. An analysis of the correlation between fatigue and QOL in the breast cancer patients showed that the overall QOL had a significant negative correlation between BFI and POMS. CONCLUSIONS: The severity of fatigue in the breast cancer patients was significantly higher than that in the healthy women, and fatigue showed a negative correlation with QOL. It was considered that the QOL of breast cancer patients was decreased due to fatigue. Therefore, healthcare professionals should not overlook fatigue in patients with breast cancer receiving hormone therapy in outpatient departments and should provide support to reduce their fatigue.
See more of: Evidence-Based Practice Poster Session 1
See more of: Evidence-Based Practice Sessions: Oral Paper & Posters
See more of: Evidence-Based Practice Sessions: Oral Paper & Posters